Syndex Bio Unveils Mcpcr Technology At Agbt 2026 Following $15.5 M Seed Financing

Syndex Bio, a biotechnology institution advancing next‑generation molecular diagnostics, coming announced nan preamble of its proprietary mcPCR™ (methyl‑copying PCR) level astatine nan Advances successful Genome Biology and Technology (AGBT) convention successful Orlando, Florida. mcPCR enables 'PCR for methylation', nan high-fidelity copying of some DNA methylation and nan four-base familial codification during DNA amplification. This overcomes a basal limitation of PCR, which cannot amplify DNA methylation patterns that are captious for nan discovery of galore diseases, including cancer. By enabling simpler, faster and much delicate study of methylated DNA, mcPCR will thief to toggle shape nan testing of objective samples, particularly successful non-invasive and small-sample biopsies for early illness discovery and recurrence monitoring.

Syndex Bio besides announced nan successful adjacent of an oversubscribed $15.5 cardinal seed financing led by ARCH Venture Partners, pinch information from +ND Capital, OMX Ventures, and Meltwind. The costs will support description of nan mcPCR platform, improvement of objective workflows and applications, and build‑out of nan company's R&D footprint successful Cambridge, UK.

In conjunction pinch nan financing, Gautam Kollu, erstwhile Chief Commercial Officer of Grail, joins nan recently formed Board of Directors alongside Patrick Weiss (Chairman), Geoff Smith, Sean Kendall, and Eric Moessinger.

"Syndex Bio's mcPCR level makes amplifying DNA methylation imaginable for nan first time. This powerful method will redefine nan sensitivity and accuracy that is achievable successful DNA methylation analysis, opening caller possibilities for early discovery and illness monitoring," said Geoff Smith, PhD, Founder and CEO of Syndex Bio. "We're honored to person nan support of world‑class investors and advisors arsenic we beforehand toward objective translation."

The mcPCR level removes nan method barriers that person agelong constricted epigenetics, yet allowing america to pat into nan highest-value segments of nan molecular diagnostics market. This capacity is basal for expanding precise objective testing crossed divers illness areas, wherever sensitivity has historically been nan bottleneck. I look guardant to helping nan squad bring specified a high-impact level exertion to nan world stage."

Gautam Kollu, Board Member, Syndex Bio

Sean Kendall, Board Member astatine Syndex Bio and Partner astatine ARCH Venture Partners, said: "This milestone is testament to Syndex Bio's talented squad and their bonzer efforts successful launching this foundational technology. We judge mcPCR holds nan imaginable to elevate nan accuracy and velocity of crab screening and test and look guardant to seeing nan institution proceed to spell from spot to strength."

The company's Founder and CEO, Geoff Smith, PhD, will coming a poster (#470) titled "mcPCR: PCR For Methylation" astatine nan AGBT General Meeting from 23-26 February 2026. Copies of nan poster will besides beryllium disposable to download from Syndex Bio's website.